Idiopathic lung fibrosis in an adult Ecuadorian from Riobamba

Authors

  • Leticia Remón Ramírez Instituto Superior de Ciencias Básicas y Preclínicas Victoria de Girón, Ciudad de la Habana, Cuba.
  • Md. Galo Uvidia Cepeda Centro de Salud Guano, Riobamba, Ecuador.
  • Orlando Jesús Castro Hayes Instituto Superior de Ciencias Básicas y Preclínicas Victoria de Girón, Ciudad de la Habana, Cuba.

Keywords:

, lung fibrosis, lung tuberculosis, chronic lung heart, Ecuador

Abstract

The case report of a 52 years patient is presented, exposed to the ashes of Tungurahua volcano in eruption,  who went to the Community Family Medicine Department of the Canton Guano, Ecuadorian province of Riobamba, for presenting productive cough in the morning, mucoid of yellowish white coloration, bad general state, evening fever, appetite  and weight loss.  According to the radiographic and topographic results, he had suggestive signs of lung tuberculosis; direct BAAR sputa and negative cultures.  The pathological findings allowed to confirm the diagnosis of idiopathic lung fibrosis. 

Downloads

Download data is not yet available.

Author Biography

Leticia Remón Ramírez, Instituto Superior de Ciencias Básicas y Preclínicas Victoria de Girón, Ciudad de la Habana, Cuba.

Especialista de I Grado en Medicina General Integral. Profesor Asistente. Instituto Superior de Ciencias Básicas y Preclínicas Victoria de Girón, La Habana, Cuba. 

References

1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9.

2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824.

3. Raghnu G, Anstrom KJ, Durham, NC, King TE, Lasky JA, Martínez FJ. Prednisone, azathriopine and n-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366:1968–77.

4. Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071-82.

5. Papakosta D, Dimadi M, Stagaki E. Prevalence of pulmonary arterial hypertension in idiophatic pulmonary fibrosis: a multicenter study. 9 th Wasog Meeting & 11 th BAL Internacional Conference. Athens, Greece PP71; 2008: 114.

6. Olson AL, Huie TJ, Groshong SD, Cosgrove GP, Janssen WJ, Schwarz MI, et al. Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest. 2008; 134(4): 844-50.

7. Xaubet A, Molina Molina M, Sánchez M. Enfermedades pulmonares intersticiales difusas. Arch Bronconeumol. 2007; 43(Supl 2): 24-30.

8. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008; 3:8.

9. García Sancho C, Buendía Roldán I, Fernández Plata MR, Navarro C, Pérez Padilla R, Vargas MH, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011; 105(12): 1902-7.

10. Bradley B, Branley HM, Egan JJ, Graves MS, Hansell DM, Harrison K. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63 (Suppl 5): v1-58.

Downloads

Published

2016-01-14

How to Cite

1.
Ramírez LR, Uvidia Cepeda MG, Castro Hayes OJ. Idiopathic lung fibrosis in an adult Ecuadorian from Riobamba. MEDISAN [Internet]. 2016 Jan. 14 [cited 2025 Jun. 4];20(1). Available from: https://medisan.sld.cu/index.php/san/article/view/479

Issue

Vol. 20 No. 1 (2016): MEDISAN

Section

Case Reports

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.